Oncology
Our commitment to multiple myeloma
This March, we are showing our support for the multiple myeloma community through education, awareness and continued research to address the unmet needs of those affected by the disease.
Investors
We announced our quarter 1 2024 results on Wednesday, May 1st.
Press releases
- Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients 12 years of age and older
- ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
- ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV


Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features